Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.

Abstract

BACKGROUND:

Chemotherapy has shown little antitumor activity against advanced oral squamous cell carcinoma (OSCC) patients. Therefore, there is an urgent need to develop more effective therapeutic methods for patients with advanced OSCC. Cepharanthine is a biscoclaurine alkaloid extracted from Stephania cepharantha Hayata, which is widely used for the treatment of many acute and chronic diseases, and can exert antitumor effects on several human cancer cells. S-1 is a new oral antineoplastic agent that can induce apoptosis in various types of cancer cells, including OSCC. Hence combined treatment of cancer cells with cepharanthine and S-1 might exert dramatic antitumor effects on OSCC cells.

MATERIALS AND METHODS:

In this study, the response of human OSCC cells to cepharanthine alone and in combination with S-1 was examined using nude mouse xenograft models. S-1 (10 mg/kg/day, 5 times/week) was administered orally and cepharanthine (20 mg/kg, 5 times/week) was injected into peritumoral tissue for three weeks. Apoptotic cells were detected by a TUNEL method. The protein expression of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and orotate phosphoribosyl transferase (OPRT) were assessed using immunohistochemistry; their gene expression was determined using microdissection and RT-PCR, and their protein levels using ELISA.

RESULTS:

Combined therapy of cepharanthine and S-1 exerted antitumor effects on human OSCC xenografts markedly and significantly induced apoptotic cells in tumors treated with cepharanthine plus S-1. Immunohistochemistry showed that the expressions of TS and DPD were down-regulated, and that OPRT expression was up-regulated in tumors treated with cepharanthine plus S-1. In the same way, microdissection and RT-PCR revealed that the expression of TS and DPD mRNA was down-regulated and that expression of OPRT mRNA was up-regulated in tumors administered the combined treatment. Moreover, ELISA indicated that the protein levels of TS and DPD were down-regulated, and that OPRT was up-regulated in tumors treated with the combined therapy. During the experimental period, no loss of body weight was observed in mice treated with the combined therapy.

CONCLUSION:

These findings demonstrate that the combination of cepharanthine and S-1 is effective against OSCC and has the potential of being a new therapeutic tool for future treatment of these tumors.

• Authors: Koji Harada, Tarannum Ferdous, Yasutaka Itashiki, Michiyo Takii, Takamichi Mano, Yoshihide Mori, Yoshiya Ueyama
• Journal: Anticancer research (Anticancer Res) Vol. 29 Issue 4 Pg. 1263-70 (Apr 2009) ISSN: 0250-7005 [Print] Greece
• PMID: 19414373 (Publication Type: Journal Article)

Chemical References

• Benzylisoquinolines
• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid
• cepharanthine
• Dihydrouracil Dehydrogenase (NADP)
• Thymidylate Synthase
• Orotate Phosphoribosyltransferase

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Apoptosis (drug effects)
• Benzylisoquinolines (administration & dosage)
• Blotting, Western
• Carcinoma, Squamous Cell (drug therapy, metabolism, secondary)
• Cell Proliferation (drug effects)
• Dihydrouracil Dehydrogenase (NADP) (metabolism)
• Drug Combinations
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Immunoenzyme Techniques
• In Situ Nick-End Labeling
• Male
• Mice
• Mice, Nude
• Mouth Neoplasms (drug therapy, metabolism, pathology)
• Orotate Phosphoribosyltransferase (metabolism)
• Oxonic Acid (administration & dosage)
• Tegafur (administration & dosage)
• Thymidylate Synthase (metabolism)
• Tumor Cells, Cultured
• Xenograft Model Antitumor Assays